An inhibitor of K+ channels modulates human endometrial tumor-initiating cells

Cancer Cell International - Tập 11 - Trang 1-7 - 2011
Brandon M Schickling1, Nukhet Aykin-Burns2,3, Kimberly K Leslie1,4, Douglas R Spitz2,3,4, Victoria P Korovkina1
1Department of Obstetrics and Gynecology, University of Iowa, Iowa City, USA
2Department of Radiation Oncology, University of Iowa, Iowa City, USA
3Free Radical and Radiation Biology Program, University of Iowa, Iowa City, USA
4Holden Comprehensive Cancer Center, University of Iowa, Iowa City, USA

Tóm tắt

Many potassium ion (K+) channels function as oncogenes to sustain growth of solid tumors, but their role in cancer progression is not well understood. Emerging evidence suggests that the early progenitor cancer cell subpopulation, termed tumor initiating cells (TIC), are critical to cancer progression. A non-selective antagonist of multiple types of K+ channels, tetraethylammonium (TEA), was found to suppress colony formation in endometrial cancer cells via inhibition of putative TIC. The data also indicated that withdrawal of TEA results in a significant enhancement of tumorigenesis. When the TIC-enriched subpopulation was isolated from the endometrial cancer cells, TEA was also found to inhibit growth in vitro. These studies suggest that the activity of potassium channels significantly contributes to the progression of endometrial tumors, and the antagonists of potassium channels are candidate anti-cancer drugs to specifically target tumor initiating cells in endometrial cancer therapy.

Tài liệu tham khảo

Stuhmer W, Pardo LA: K(+) channels as therapeutic targets in oncology. Future Med Chem. 2010, 2: 745-755. 10.4155/fmc.10.24.

Asher V, Sowter H, Shaw R, Bali A, Khan R: Eag and HERG potassium channels as novel therapeutic targets in cancer. World J Surg Oncol. 2010, 8: 113-10.1186/1477-7819-8-113.

Ernest NJ, Logsdon NJ, McFerrin MB, Sontheimer H, Spiller SE: Biophysical properties of human medulloblastoma cells. J Membr Biol. 2010, 237: 59-69. 10.1007/s00232-010-9306-x.

Bielanska J, Hernandez-Losa J, Perez-Verdaguer M, Moline T, Somoza R, Ramon YCS, Condom E, Ferreres JC, Felipe A: Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets. 2009, 9: 904-914. 10.2174/156800909790192400.

Wondergem R, Bartley JW: Menthol increases human glioblastoma intracellular Ca2+, BK channel activity and cell migration. J Biomed Sci. 2009, 16: 90-10.1186/1423-0127-16-90.

Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, Couraud PO, Ningaraj NS: Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer. 2009, 9: 258-10.1186/1471-2407-9-258.

Brevet M, Haren N, Sevestre H, Merviel P, Ouadid-Ahidouch H: DNA methylation of K(v)1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma. Cell Physiol Biochem. 2009, 24: 25-32. 10.1159/000227810.

Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M: Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol. 2010, 41: 1516-1529. 10.1016/j.humpath.2010.05.006.

Chantome A, Girault A, Potier M, Collin C, Vaudin P, Pages JC, Vandier C, Joulin V: KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res. 2009, 315: 3620-3630. 10.1016/j.yexcr.2009.07.021.

Blackiston DJ, McLaughlin KA, Levin M: Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle. 2009, 8: 3519-3528.

Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M, Catalano M, D'Alessandro G, Santoro A, Cantore G, Ragozzino D, Castigli E, Franciolini F, Limatola C: CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol. 2010, 299: C175-184. 10.1152/ajpcell.00344.2009.

Becchetti A, Arcangeli A: Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 2010, 674: 107-123. 10.1007/978-1-4419-6066-5_10.

Haren N, Khorsi H, Faouzi M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H: Intermediate conductance Ca2+ activated K+ channels are expressed and functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol Histopathol. 2010, 25: 1247-1255.

Lee I, Park C, Kang WK: Knockdown of inwardly rectifying potassium channel Kir2.2 suppresses tumorigenesis by inducing reactive oxygen species-mediated cellular senescence. Mol Cancer Ther. 2010, 9: 2951-2959. 10.1158/1535-7163.MCT-10-0511.

Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A, Arcangeli A: Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer. 2010, 10: 504-10.1186/1471-2407-10-504.

Tajima N, Itokazu Y, Korpi ER, Somerharju P, Kakela R: Activity of BK(Ca) channel is modulated by membrane cholesterol content and association with Na+/K+-ATPase in human melanoma IGR39 cells. J Biol Chem. 2011, 286: 5624-5638. 10.1074/jbc.M110.149898.

Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, Sowter HM: The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010, 5: 78-10.1186/1746-1596-5-78.

Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A, Roger S: P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011, 30: 2108-2122. 10.1038/onc.2010.593.

Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, Urbain R, Gosset P, Delcourt P, Fleurisse L, Slomianny C, Dewailly E, Mauroy B, Bonnal JL, Skryma R, Prevarskaya N: Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009, 28: 1792-1806. 10.1038/onc.2009.25.

Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R: The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int. 2011, 11: 6-10.1186/1475-2867-11-6.

Kim HJ, Jang SH, Jeong YA, Ryu PD, Kim DY, Lee SY: Involvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. Biol Pharm Bull. 2010, 33: 1754-1757. 10.1248/bpb.33.1754.

Biderman B, Marakhonov A, Skoblov M, Birerdinc A, Nohelty E, Page S, Khomenkov V, Chandhoke V, Sudarikov A, Nikitin E, Baranova A: Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia. Drug News Perspect. 2010, 23: 625-631. 10.1358/dnp.2010.23.10.1507740.

Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M, Basso G, Becchetti A, Campana D, Arcangeli A: Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood. 2011, 117: 902-914. 10.1182/blood-2010-01-262691.

Agarwal JR, Griesinger F, Stuhmer W, Pardo LA: The potassium channel Ether a go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010, 9: 18-10.1186/1476-4598-9-18.

Jang SH, Kang KS, Ryu PD, Lee SY: Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. BMB Rep. 2009, 42: 535-539. 10.5483/BMBRep.2009.42.8.535.

Dolderer JH, Schuldes H, Bockhorn H, Altmannsberger M, Lambers C, von Zabern D, Jonas D, Schwegler H, Linke R, Schroder UH: HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol. 2010, 36: 72-77.

Teng IW, Hou PC, Lee KD, Chu PY, Yeh KT, Jin VX, Tseng MJ, Tsai SJ, Chang YSD, Wu CS, Sun HS, Tsai KD, Jeng LB, Nephew KP, Huang TH, Hsiao SH, Leu YW: Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 2011

Kano M, Tsukahara T, Emori M, Murase M, Torigoe T, Kawaguchi S, Wada T, Yamashita T, Sato N: Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci. 2011

Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, Olson S, Gabrielli B, Osborne G, Vescovi A, Reynolds BA: Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain. 2011, 134: 1331-1343. 10.1093/brain/awr081.

Albitar L, Pickett G, Morgan M, Davies S, Leslie KK: Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol. 2007, 106: 52-64. 10.1016/j.ygyno.2007.02.033.

Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M, Arcangeli A: HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer. 2000, 83: 1722-1729. 10.1054/bjoc.2000.1497.

Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, Wang YZ: Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer. Oncogene. 2007, 26: 5107-5114. 10.1038/sj.onc.1210308.

Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP: Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010, 140: 62-73. 10.1016/j.cell.2009.12.007.

Heerma van Voss MR, van der Groep P, Bart J, van der Wall E, van Diest PJ: Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer. Cell Oncol (Dordr). 2011, 34: 3-10.

Rahadiani N, Ikeda J, Mamat S, Matsuzaki S, Ueda Y, Umehara R, Tian T, Wang Y, Enomoto T, Kimura T, Aozasa K, Morii E: Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer Sci. 2011, 102: 903-908. 10.1111/j.1349-7006.2011.01864.x.

Kusumbe AP, Bapat SA: Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009, 69: 9245-9253. 10.1158/0008-5472.CAN-09-2802.

Potier M, Chantome A, Joulin V, Girault A, Roger S, Besson P, Jourdan ML, LeGuennec JY, Bougnoux P, Vandier C: The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol. 2011, 162: 464-479. 10.1111/j.1476-5381.2010.01044.x.

Thông tin
Thông tin xuất bản

Cancer Cell International

Tập 11

1-7

Thông tin tác giả